Ines Santolini Selected Research

N- cyclobutyl- 6- ((3- fluorophenyl)ethynyl)nicotinamide

11/2020	Pharmacological activation of mGlu5 receptors with the positive allosteric modulator VU0360172, modulates thalamic GABAergic transmission.
7/2016	The anti-absence effect of mGlu5 receptor amplification with VU0360172 is maintained during and after antiepileptogenesis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ines Santolini Research Topics

Disease

6	Absence Epilepsy (Childhood Absence Epilepsy) 11/2020 - 07/2011
4	Seizures (Absence Seizure) 07/2018 - 08/2010
2	Epilepsy (Aura) 01/2019 - 11/2017
1	Generalized Epilepsy 11/2017
1	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 04/2011
1	Ischemia 04/2011

Drug/Important Bio-Agent (IBA)

2	N- cyclobutyl- 6- ((3- fluorophenyl)ethynyl)nicotinamideIBA 11/2020 - 07/2016
2	Metabotropic Glutamate Receptors (Metabotropic Glutamate Receptor)IBA 01/2019 - 07/2011
2	ThrombospondinsIBA 11/2017 - 01/2017
2	LigandsIBA 11/2017 - 01/2017
2	Glutamic Acid (Glutamate)FDA Link 07/2011 - 04/2011
1	Glutamate Receptors (Glutamate Receptor)IBA 01/2019
1	Melatonin Receptors (Melatonin Receptor)IBA 07/2018
1	MelatoninIBA 07/2018
1	Immunoglobulin E (IgE)IBA 11/2017
1	Gabapentin (Neurontin)FDA LinkGeneric 01/2017
1	Pregabalin (Lyrica)FDA Link 01/2017
1	T-Type Calcium Channels (T-Type Calcium Channel)IBA 01/2017
1	Calcium Channels (Calcium Channel)IBA 01/2017
1	Pharmaceutical PreparationsIBA 07/2016
1	Ethosuximide (Zarontin)FDA LinkGeneric 07/2016
1	Endothelin-1 (Endothelin 1)IBA 04/2011
1	CannabinoidsIBA 08/2010
1	PlasticsIBA 08/2010

Therapy/Procedure

1	Pinealectomy 07/2018
1	Therapeutics 07/2016